Picture Informa Connect BioProcess Intl Europe 2025 Hamburg Agenda 650x100px

Collaboration › Details

Bayer–Puhe BioPharma: PRMT5 inhibitor, 202503– license ww excl €na to PH020 / BAY 3713372 from Suzhou Puhe BioPharma Co Ltd

	Period	2025-03-26
	Region	ALL
	Partner, 1st	Bayer Pharma division
	Group	Bayer (Group)
	Partner, 2nd	Suzhou Puhe BioPharma Co.,Ltd.
	Group	Puhe BioPharma (Group)
	Product	BAY 3713372 (formerly PH020, Bayer / Puhe BioPharma)
	Product 2	drug development
	Person	Eckhardt, Jürgen (Bayer 201904 Head of Leaps by Bayer)
	Person 2	Rüttinger, Dominik (Bayer 202110– Head of Research + Early Development for Oncology before Roche pRED + Micromet)
	Source	Bayer AG. (3/26/25). "Press Release: Bayer and Puhe BioPharma Enter into Global License Agreement for Clinical Phase I PRMT5 inhibitor [Not intended for U.S. and UK Media]". Berlin & Beijing.

Record changed: 2025-03-31

Picture Swiss Biotech Association Global Village 2025 SBD25 Basel 650x200px

More documents for Bayer (Group)

[1] Bayer AG. (3/26/25). "Press Release: Bayer and Puhe BioPharma Enter into Global License Agreement for Clinical Phase I PRMT5 inhibitor [Not intended for U.S. and UK Media]". Berlin & Beijing....
[2] Roivant Sciences GmbH. (9/10/24). "Press Release: Roivant Unveils New Pipeline Program Mosliciguat, a Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator". Basel, London & New York, NY....
[3] NextRNA Therapeutics, Inc.. (8/28/24). "Press Release: Bayer and NextRNA Therapeutics Enter Strategic Collaboration to Develop Small Molecules Targeting Long Non-coding RNAs (lncRNAs) in Oncology". Berlin & Boston, MA....
[4] Bayer AG. (7/17/24). "Press Release: Darolutamide Meets Primary Endpoint in Phase III ARANOTE Trial in Men with Metastatic Hormone-sensitive Prostate Cancer [Not intended for U.S. and UK Media]". Berlin....
[5] BlueRock Therapeutics LP. (5/30/23). "Press Release: BlueRock Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for Parkinson’s Disease Cell Therapy Candidate Bemdaneprocel". Berlin & Cambridge, MA....
[6] H. Lundbeck A/S. (5/13/24). "Press Release: Maria Alfaiate Appointed New Executive Vice President Commercial and Corporate Strategy at Lundbeck"....
[7] WhiteLab Genomics. (5/6/24). "Press Release: WhiteLab Genomics Establishes US Presence by Securing Spot at Bayer Co.Lab and Ginkgo Bioworks’ Technology Network". Cambridge, MA....
[8] Evotec SE. (4/30/24). "Press Release: Bayer and Evotec Collaborate to Advance Precision Cardiology". Berlin & Hamburg....
[9] ProBioGen AG. (4/30/24). "Press Release: Change in Management". Berlin....
[10] Aignostics GmbH. (3/14/24). "Press Release: Bayer and Aignostics to Collaborate on Next Generation Precision Oncology"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)